一分钟看懂
这是一项关于乳腺癌的III 期研究，登记的药物或干预包括HRS-8080 Tablet；Fulvestrant injection；Exemestane tablets；Everolimus Tablets；Anastrozole Tablets；Letrozole Tablets，当前状态为招募中。登记地点显示中国广州、长沙有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
HRS-8080 Tablet；Fulvestrant injection；Exemestane tablets；Everolimus Tablets；Anastrozole Tablets；Letrozole Tablets · III 期
登记条件中文摘要
年龄范围：18岁至75岁
登记的基本范围为女性，年龄18岁至75岁；以下仅摘录8项专业入选条件，需结合英文原文并由研究团队确认。
登记记录列出8项主要排除条件，具体医学含义需结合英文原文并由研究团队确认。
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Sun Yat-sen University Cancer Center · 广州
- Hunan Cancer Hospital · 长沙
入选条件原文摘录
以下为摘录，请打开原始登记查看完整入排标准。
- 1. Women aged 18 to 75 years old (including both values).
- 2. ECOG Physical Strength Status (PS) : 0 to 1 point.
- 3. Patients with locally advanced or metastatic breast cancer confirmed by histology.
- 4. Patients previously received 1-2 lines of endocrine therapy.
- 5. Patients received no more than one line of chemotherapy in the recurrence/metastasis stage.
- 6. Menstrual status (meeting any of the following conditions) : a) After bilateral ovariectomy; b) Age ≥60 years old; c) Age \< 60 years old, natural menopause ≥12 months, without receiving chemotherapy, tamoxifen (TAM), tolemiphene or ovarian castration in the past year, follicle-stimulating hormone (FSH) and estradiol are within the postmenopausal range; d) For patients under the age of 60 who are taking TAM or tolemiphene, the levels of FSH and estradiol are within the postmenopausal range; e) Premenopausal or perimenopausal patients received luteinizing hormone-releasing hormone (LHRH) agonist treatment during the study period, and the treatment was initiated at least 14 days before the start of the study.
- 7. Patients comply with any of the following provisions of the RECIST v1.1 standard: a) There is at least one extracranial measurable lesion; b) If there are no measurable lesions as stipulated above, at least one osteolytic or mixed (osteolytic and osteogenic) bone lesion that can be evaluated by computed tomography (CT) or magnetic resonance imaging (MRI) exists.
- 8. Expected survival \> 6 months.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT07024173；登记信息更新于 2026-10-02；本站同步于 2026-10-08。